Picard Medical Securities Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy PMI?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements during the class period, failing to disclose significant adverse facts about its business and securities trading, which led to investor losses.
- Fraudulent Activities Uncovered: Specific allegations include involvement in a fraudulent stock promotion scheme via social media misinformation and insiders using offshore accounts to manipulate share prices, severely impacting investor perceptions of the company's prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Securities Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, that they must apply to be lead plaintiff by April 13, 2026, or risk losing the opportunity to represent other investors in the class action.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements and failed to disclose significant adverse facts about its business and securities trading during the class period, particularly involving a fraudulent stock promotion scheme utilizing social media.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its expertise and success in this legal domain.
- Investor Action Recommendations: Investors are encouraged to visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to represent them in the lawsuit and avoid inexperienced middlemen.
See More
Multiple Companies Facing Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations of making false statements regarding a supposed collaboration with Microsoft during the class period from January 27 to January 29, 2026, leading to investor misconceptions about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Plug Power Lawsuit: Plug Power, Inc. is accused of overstating the availability of funds related to a DOE loan during the class period from January 17, 2025, to November 13, 2025, which may force the company to pivot to smaller projects, with the same lead plaintiff deadline of April 3, 2026.
- Picard Medical Lawsuit: Picard Medical, Inc. is implicated in a fraudulent stock promotion scheme involving misinformation on social media from September 2 to October 31, 2025, resulting in manipulated stock prices, with a lead plaintiff deadline of April 3, 2026.
- BlackRock TCP Lawsuit: BlackRock TCP Capital Corp. is accused of failing to appropriately value investments from November 6, 2024, to January 23, 2026, leading to an overstatement of the company's net asset value, with a lead plaintiff deadline of April 6, 2026.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Picard Medical, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors needing to apply as Lead Plaintiff by April 3, 2026.
- Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 to an all-time high of $13.68, despite the absence of any fundamental news to justify such a dramatic increase.
- Social Media Manipulation: Investigations have revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors created a buying frenzy among retail investors through sensational but unfounded claims, artificially inflating the stock price.
- Law Firm Credentials: Pomerantz LLP is recognized as a premier firm in corporate, securities, and antitrust class litigation, founded over 85 years ago, and continues to advocate for victims of securities fraud and corporate misconduct, having secured numerous multimillion-dollar damages awards for class members.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Picard Medical for potential violations of federal securities laws between September 2 and October 31, 2025, which may have led to investor losses, urging investors to apply as lead plaintiffs by April 13, 2026.
- Stock Price Plummet: On October 24, 2025, Picard Medical's shares fell from $13.20 to $5.31, a staggering drop of $7.89 or 59.8% in a single day, marking one of the most significant declines since its IPO, raising serious concerns about the company's financial health.
- False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives engaged in fraudulent stock promotion schemes via social media, failing to disclose insider trading activities that misled investors about the company's prospects, exacerbating stock price volatility.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact them to provide information or participate in the lawsuit, ensuring their legal rights are protected, particularly those who may wish to serve as lead plaintiffs.
See More
Faruqi & Faruqi Encourages Picard Investors to Reach Out
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Picard Medical, focusing on investors who purchased securities between September 2, 2025, and October 31, 2025, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to help them understand their legal rights.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, emphasizing the importance of timely action.
- Market Reaction: This news may negatively impact Picard Medical's stock price, prompting investors to monitor subsequent legal developments and their potential effects on the company's financial health.
See More
Class Action Notice for Picard Medical Investors Amid Fraud Allegations
- Class Action Initiation: The Portnoy Law Firm has initiated a class action on behalf of investors who purchased Picard Medical securities between September 5 and October 31, 2025, with a deadline of April 3, 2026, for filing lead plaintiff motions to protect their legal rights.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70% from $13.30 to $3.99 per share due to undisclosed fraudulent stock promotion schemes, and it has since continued to decline to approximately $2.00, significantly impacting investor asset values.
- Fraud Allegations Details: The lawsuit alleges that Picard failed to disclose a fraudulent stock promotion scheme involving social media misinformation and impersonated financial professionals, leading to artificial stock price manipulation and substantial investor losses.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations to assist investors in recovering losses due to corporate wrongdoing, with the founding partner having successfully recovered over $5.5 billion for aggrieved investors, demonstrating strong capability in such cases.
See More
Picard Medical Securities Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, that they must apply to be lead plaintiff by April 13, 2026, or risk losing the opportunity to represent other investors in the class action.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements and failed to disclose significant adverse facts about its business and securities trading during the class period, particularly involving a fraudulent stock promotion scheme utilizing social media.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its expertise and success in this legal domain.
- Investor Action Recommendations: Investors are encouraged to visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to represent them in the lawsuit and avoid inexperienced middlemen.
See More
Multiple Companies Facing Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations of making false statements regarding a supposed collaboration with Microsoft during the class period from January 27 to January 29, 2026, leading to investor misconceptions about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Plug Power Lawsuit: Plug Power, Inc. is accused of overstating the availability of funds related to a DOE loan during the class period from January 17, 2025, to November 13, 2025, which may force the company to pivot to smaller projects, with the same lead plaintiff deadline of April 3, 2026.
- Picard Medical Lawsuit: Picard Medical, Inc. is implicated in a fraudulent stock promotion scheme involving misinformation on social media from September 2 to October 31, 2025, resulting in manipulated stock prices, with a lead plaintiff deadline of April 3, 2026.
- BlackRock TCP Lawsuit: BlackRock TCP Capital Corp. is accused of failing to appropriately value investments from November 6, 2024, to January 23, 2026, leading to an overstatement of the company's net asset value, with a lead plaintiff deadline of April 6, 2026.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Picard Medical, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors needing to apply as Lead Plaintiff by April 3, 2026.
- Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 to an all-time high of $13.68, despite the absence of any fundamental news to justify such a dramatic increase.
- Social Media Manipulation: Investigations have revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors created a buying frenzy among retail investors through sensational but unfounded claims, artificially inflating the stock price.
- Law Firm Credentials: Pomerantz LLP is recognized as a premier firm in corporate, securities, and antitrust class litigation, founded over 85 years ago, and continues to advocate for victims of securities fraud and corporate misconduct, having secured numerous multimillion-dollar damages awards for class members.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Picard Medical for potential violations of federal securities laws between September 2 and October 31, 2025, which may have led to investor losses, urging investors to apply as lead plaintiffs by April 13, 2026.
- Stock Price Plummet: On October 24, 2025, Picard Medical's shares fell from $13.20 to $5.31, a staggering drop of $7.89 or 59.8% in a single day, marking one of the most significant declines since its IPO, raising serious concerns about the company's financial health.
- False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives engaged in fraudulent stock promotion schemes via social media, failing to disclose insider trading activities that misled investors about the company's prospects, exacerbating stock price volatility.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact them to provide information or participate in the lawsuit, ensuring their legal rights are protected, particularly those who may wish to serve as lead plaintiffs.
See More
Faruqi & Faruqi Encourages Picard Investors to Reach Out
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Picard Medical, focusing on investors who purchased securities between September 2, 2025, and October 31, 2025, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to help them understand their legal rights.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, emphasizing the importance of timely action.
- Market Reaction: This news may negatively impact Picard Medical's stock price, prompting investors to monitor subsequent legal developments and their potential effects on the company's financial health.
See More
Class Action Notice for Picard Medical Investors Amid Fraud Allegations
- Class Action Initiation: The Portnoy Law Firm has initiated a class action on behalf of investors who purchased Picard Medical securities between September 5 and October 31, 2025, with a deadline of April 3, 2026, for filing lead plaintiff motions to protect their legal rights.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70% from $13.30 to $3.99 per share due to undisclosed fraudulent stock promotion schemes, and it has since continued to decline to approximately $2.00, significantly impacting investor asset values.
- Fraud Allegations Details: The lawsuit alleges that Picard failed to disclose a fraudulent stock promotion scheme involving social media misinformation and impersonated financial professionals, leading to artificial stock price manipulation and substantial investor losses.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations to assist investors in recovering losses due to corporate wrongdoing, with the founding partner having successfully recovered over $5.5 billion for aggrieved investors, demonstrating strong capability in such cases.
See More
